articleTop 1% cited
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
The Lancet Oncology · 2015 · Vol. 16(2) · pp. 152–160
Charles J. Ryan✉(University of California, San Francisco)Matthew R. Smith(Harvard University)Karim Fizazi(Université Paris-Sud)Fred Saad(Université de Montréal)Peter F.A. Mulders(Radboud University Nijmegen)Cora N. Sternberg(Carlo Forlanini Hospital)Kurt Miller(Charité - Universitätsmedizin Berlin)Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center)Neal D. Shore(Carolina Urologic Research Center)Eric J. Small(University of California, San Francisco)Joan Carles(Hebron University)Thomas W. Flaig(University of Colorado Cancer Center)Mary-Ellen Taplin(Harvard University)Celestia S. Higano(University of Washington)Paul de Souza(Ingham Institute)Johann S. de Bono(Institute of Cancer Research)Thomas W. Griffin(Janssen (Belgium))Peter De Porre(Janssen (Belgium))Margaret K. Yu(Janssen (Belgium))Youn C. Park(Janssen (United States))Jinhui Li(Janssen (United States))Thian Kheoh(Janssen (Belgium))Vahid Naini(Janssen (Belgium))Arturo Molina(Menlo School)Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center)
Prostate Cancer Treatment and ResearchHormonal and reproductive studiesProstate Cancer Diagnosis and TreatmentAbiraterone acetatePrednisoneMedicineProstate cancerPlaceboInternal medicineOncologyCastrationUrologyAbiraterone
MeSH terms
AgedAndrostenesAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsDouble-Blind MethodFollow-Up StudiesHumansMaleNeoplasm StagingPrednisonePrognosisSurvival RateDisease ProgressionAntineoplastic Agents, HormonalProstatic Neoplasms, Castration-Resistant
Funding
- Janssen Research and Development
Citations
1,334
FWCI
115.51
field-weighted impact
References
26
Percentile
100%
vs. same field & year
Citations per year
Cited by
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
European Urology · 2020 · 1,110 citations
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
European Urology · 2016 · 1,439 citations
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Frontiers in Oncology · 2019 · 305 citations
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2020 · 931 citations
References
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
The Lancet Oncology · 2012 · 1,374 citations
The Statistical Analysis of Failure Time Data.
Biometrics · 1981 · 9,990 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.